Rebecca completed her B.S. in Biological Sciences at the University of Maryland, College Park in 2018. After a post-baccalaureate fellowship at the U.S. Food and Drug Administration's Laboratory of Immunobiology, she joined the Cancer ImmunoPrevention Laboratory at the Frederick National Laboratory for Cancer Research in 2020. There, she assesses immunogenicity of preclinical cancer vaccines and tests a COVID-19 therapeutic in preparation for a phase I clinical trial.